Umeå University's logo

umu.sePublications
Change search
Link to record
Permanent link

Direct link
Granger, Christopher B.ORCID iD iconorcid.org/0000-0002-0045-3291
Publications (1 of 1) Show all publications
Teo, K. K., Sleight, P., Gao, P., Yusuf, S., Connolly, S., Swedberg, K., . . . Weber, M. (2011). Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals The ARB Trialists Collaboration. Journal of Hypertension, 29(4), 623-635
Open this publication in new window or tab >>Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals The ARB Trialists Collaboration
Show others...
2011 (English)In: Journal of Hypertension, ISSN 0263-6352, E-ISSN 1473-5598, Vol. 29, no 4, p. 623-635Article, review/survey (Refereed) Published
Abstract [en]

Background Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) reduce cardiovascular disease (CVD) events, but a recent meta-analysis of selected studies suggested that ARBs may increase cancer risks.

Objective Candesartan, irbesartan, telmisartan, valsartan, and losartan were assessed for incident cancers in 15 large parallel long-term multicenter double-blind clinical trials of these agents involving 138 769 participants.

Patients and methods Individuals at high CVD risk were randomized to telmisartan (three trials, n=51 878), irbesartan (three trials, n=14 859), valsartan (four trials, n=44 264), candesartan (four trials, n=18 566), and losartan (one trial, n=9193) and followed for 23-60 months. Incident cancer cases were compared in patients randomized to ARBs versus controls. In five trials (n=42 403), the ARBs were compared to ACEi and in 11 trials (n=63 313) to controls without ACEi. In addition, in seven trials (n=47 020), the effect of ARBs with ACEi was compared to ACEi alone and in two trials ARBs with ACEi versus ARB alone (n=25 712).

Results Overall, there was no excess of cancer incidence with ARB therapy compared to controls in the 15 trials [ 4549 (6.16%) cases of 73 808 allocated to ARB versus 3856 (6.31%) of 61 106 assigned to non-ARB controls; odds ratio (OR) 1.00, 95% confidence interval (CI) 0.95-1.04] overall or when individual ARBs were examined. ORs comparing combination therapy with ARB along with ACEi versus ACEi was 1.01 (95% CI 0.94-1.10), combination versus ARB alone 1.02 (95% CI 0.91-1.13), ARB alone versus ACEi alone 1.06 (95% CI 0.97-1.16) and ARB versus placebo/control without ACEi 0.97 (95% CI 0.91-1.04). There was no excess of lung, prostate or breast cancer, or overall cancer deaths associated with ARB treatment.

Conclusion There was no significant increase in the overall or site-specific cancer risk from ARBs compared to controls.

Keywords
angiotensin receptor blockers, cancer incidence, candesartan, clinical trials, irbesartan, losartan, meta-analysis, telmisartan, valsartan
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-104472 (URN)10.1097/HJH.0b013e328344a7de (DOI)000288199500001 ()
Available from: 2015-06-16 Created: 2015-06-11 Last updated: 2018-06-07Bibliographically approved
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-0045-3291

Search in DiVA

Show all publications